-
-
-
-
-
-
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
-
-
-
-
-
-
-
Valneva and Pfizer Announce Closing of Equity Investment
-
-
-
-
-
-
-
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
-
-
-
-
-
-
-
Valneva Reports Nine Month Results Marked by Further Major Corporate Achievements
-
-
-
-
-
-
-
VALNEVA Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones
-
-
-
-
-
-
-
VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017
-
-
-
-
-
-
-
Valneva Posts 96% Revenue Growth in 2015; Forecasts 2016 Revenues of EU90 to EU100 Million
-
1,197,523 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

